Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Complexation Equilibria: The Chelate Effect

Complexation Equilibria: The Chelate Effect

In complexation reactions, metal atoms or cations interact with ligands to form donor-acceptor adducts called metal complexes. Ligands that bind through one donor site are monodentate, ligands with two donor sites are bidentate, and those with more than two donor sites are polydentate ligands. For example, ethylene diamine is a bidentate ligand that binds through two nitrogen donor atoms, forming a five-membered ring. EDTA is a polydentate ligand that binds through four oxygen and two nitrogen...

EDTA: Chemistry and Properties

EDTA: Chemistry and Properties

Polydentate ligands are most widely used in complexometric titrations because they form more stable complexes with the metal ions than mono- or bidentate ligands due to the chelate effect. Examples of polydentate ligands are ethylenediaminetetraacetic acid (EDTA), crown ethers, and cryptands. The most important feature of optimal polydentate ligands is the ability to form 1:1 complexes in a single-step process. Amino carboxylic acid derivatives are frequently used as complexing agents. EDTA is...

Extraction: Advanced Methods

Extraction: Advanced Methods

Metal ions can be separated from one another by complexation with organic ligands–the chelating agent– to form uncharged chelates. Here, the chelating agent must contain hydrophobic groups and behave as a weak acid, losing a proton to bind with the metal. Since most organic ligands used in this process are insoluble or undergo oxidation in the aqueous phase, the chelating agent is initially added to the organic phase and extracted into the aqueous phase. The metal-ligand complex is formed in...

Antiprotozoal Agents

Antiprotozoal Agents

Leishmaniasis is a widespread parasitic disease caused by several Leishmania species. It affects millions of people each year and remains a major public health problem in endemic regions. First-line treatment relies on pentavalent antimonials, including meglumine antimoniate and sodium stibogluconate. Even so, how these drugs work has not been fully clear, especially their interaction with parasite-specific biochemical pathways. One key target is trypanothione reductase (TR), an enzyme that...

Metal-Ligand Bonds

Metal-Ligand Bonds

The hemoglobin in the blood, the chlorophyll in green plants, vitamin B-12, and the catalyst used in the manufacture of polyethylene all contain coordination compounds. Ions of the metals, especially the transition metals, are likely to form complexes.
In these complexes, transition metals form coordinate covalent bonds, a kind of Lewis acid-base interaction in which both of the electrons in the bond are contributed by a donor (Lewis base) to an electron acceptor (Lewis acid). The Lewis acid in...

EDTA: Auxiliary Complexing Reagents

EDTA: Auxiliary Complexing Reagents

EDTA titrations are usually carried out in highly basic conditions, where the fully deprotonated form of EDTA, Y4−, actively complexes with the free metal ions in the solution. Several metal ions precipitate as hydrous oxide (hydroxides, oxides, or oxyhydroxides) under these conditions, lowering the concentration of free metal ions in the solution. For this reason, auxiliary complexing agents or ligands such as ammonia, tartrate, citrate, or triethanolamine are used in EDTA titrations to...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

[Implementation of biosecurity measures by hoof trimmers in Switzerland].

Schweizer Archiv fur Tierheilkunde·2023

Same author

[Prevalence of claw disorders in swiss cattle farms].

Schweizer Archiv fur Tierheilkunde·2021

Same author

[Evaluation of a novel training course for hoof trimmers to participate in a Swiss national cattle claw health monitoring programme].

Schweizer Archiv fur Tierheilkunde·2021

Same author

Rapamycin-based graft-versus-host disease prophylaxis increases the immunosuppressivity of myeloid-derived suppressor cells without affecting T cells and anti-tumor cytotoxicity.

Clinical and experimental immunology·2020

Same author

The Refeeding Syndrome revisited: you can only diagnose what you know.

European journal of clinical nutrition·2019

Same author

Nimotuzumab and radiotherapy for treatment of newly diagnosed diffuse intrinsic pontine glioma (DIPG): a phase III clinical study.

Journal of neuro-oncology·2019

Search research articles

Related Experiment Video

Updated: Jul 14, 2026

Quantifiable and Inexpensive Cell-Free Fluorescent Method to Confirm the Ability of Novel Compounds to Chelate Iron

Quantifiable and Inexpensive Cell-Free Fluorescent Method to Confirm the Ability of Novel Compounds to Chelate Iron

Published on: February 23, 2024

Recent developments in iron chelation therapy.

H Cario¹, G Janka-Schaub, G Janssen

¹Klinik für Kinder- und Jugendmedizin, Universitätsklinikum Ulm, Eythstrasse 24, 89075 Ulm. holger.cario@uniklinik-ulm.de

Klinische Padiatrie

|May 26, 2007

Summary

Iron overload can now be treated with three chelating agents: desferrioxamine (DFO), deferiprone (DFP), and deferasirox (DSX). New methods like cardiac MRI assess treatment effectiveness, improving patient outcomes.

More Related Videos

Continuous Manual Exchange Transfusion for Patients with Sickle Cell Disease: An Efficient Method to Avoid Iron Overload

Continuous Manual Exchange Transfusion for Patients with Sickle Cell Disease: An Efficient Method to Avoid Iron Overload

Published on: March 14, 2017

Dynamic Light Scattering Analysis for the Determination of the Particle Size of Iron-Carbohydrate Complexes

Dynamic Light Scattering Analysis for the Determination of the Particle Size of Iron-Carbohydrate Complexes

Published on: July 7, 2023

Related Experiment Videos

Last Updated: Jul 14, 2026

Quantifiable and Inexpensive Cell-Free Fluorescent Method to Confirm the Ability of Novel Compounds to Chelate Iron

Quantifiable and Inexpensive Cell-Free Fluorescent Method to Confirm the Ability of Novel Compounds to Chelate Iron

Published on: February 23, 2024

Continuous Manual Exchange Transfusion for Patients with Sickle Cell Disease: An Efficient Method to Avoid Iron Overload

Continuous Manual Exchange Transfusion for Patients with Sickle Cell Disease: An Efficient Method to Avoid Iron Overload

Published on: March 14, 2017

Dynamic Light Scattering Analysis for the Determination of the Particle Size of Iron-Carbohydrate Complexes

Dynamic Light Scattering Analysis for the Determination of the Particle Size of Iron-Carbohydrate Complexes

Published on: July 7, 2023

Area of Science:

Hematology
Pharmacology
Medical Imaging

Background:

Secondary hemosiderosis treatment has evolved since 1962, initially relying on desferrioxamine (DFO) via subcutaneous infusion.
The development of oral iron chelators, like deferiprone (DFP), faced challenges but is now used for thalassemia major.
Recent advancements include new iron overload assessment methods and novel chelating agents, improving patient care.

Purpose of the Study:

To review the progress in iron chelation therapy for secondary hemosiderosis.
To highlight the efficacy of different chelating agents, including oral options.
To discuss the impact of new assessment methods on treatment strategies.

Main Methods:

Review of clinical research and drug development in iron chelation.
Utilizing cardiac T2 (*) MRI to assess myocardial siderosis.
Analysis of clinical trials comparing DFO, DFP, and deferasirox (DSX).

Main Results:

Cardiac T2 (*) MRI studies suggest deferiprone (DFP) is superior to desferrioxamine (DFO) for myocardial siderosis.
Combination therapy with DFO and DFP shows additive/synergistic effects for iron elimination.
Deferasirox (DSX) demonstrates good efficacy and tolerability in transfusional hemosiderosis.

Conclusions:

Patients now have a choice of three chelating agents: DFO, DFP, and DSX.
Tailored treatment strategies can lead to improved life expectancy and quality of life.
Ongoing research, particularly long-term studies on DSX, will further define optimal iron overload management.